The Latest Breaking News from Takeda Pharmaceutical Company Limited

The pharmaceutical industry is growing amid the adoption of enhanced technologies such as AI and new drug discoveries. Given the industry’s long-term solid prospects, pharma stocks Sanofi (SNY), Takeda Pharmaceutical (TAK), and Calliditas Therapeutics (CALT) could be worth adding to your watchlist. Read on.

Despite macroeconomic headwinds, the pharmaceutical industry is anticipated to stay buoyed in the foreseeable future, owing to rising healthcare spending. Against this backdrop, we think the strong fundamentals of Novo Nordisk (NVO), Bristol-Myers Squibb (BMY), and Takeda Pharmaceutical (TAK) make them wise portfolio additions. Read on….

The benchmark indices again ended in the red in the last trading session. With market volatility expected to remain, value investing is gaining traction. We think fundamentally sound stocks Tyson Foods (TSN), LyondellBasell (LYB), Takeda Pharmaceuticals (TAK), Bayer AG (BAYRY), and AutoNation (AN), which are currently trading at a discount,…

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal 2021 core net profit of ¥663.7 billion, an increase of 1.3% from the prior year. Core earnings per share reached ¥425, up 1.2%. FY21 net profit declined 38.8% to ¥230.1 billion. Fiscal 2021 core revenue was ¥3.42 trillion, an underlying increase of 7.4%. Gastroenterology…

Yesterday, the Federal Reserve implemented its first 50-basis-point interest rate hike since 2000 to tame rising inflation. The volatility in the stock market has been increasing with the Fed’s monetary policy pivot, historically high levels of inflation, and the Russia-Ukraine war. And analysts expect the S&P 500 to plunge further.…

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…